---
provider: openai
model: o3-deep-research-2025-06-26
cached: false
start_time: '2025-12-27T15:25:57.898849'
end_time: '2025-12-27T15:44:59.293183'
duration_seconds: 1141.39
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: AP4B1
  gene_symbol: AP4B1
  uniprot_accession: Q9Y6B7
  protein_description: 'RecName: Full=AP-4 complex subunit beta-1 {ECO:0000305}; AltName:
    Full=AP-4 adaptor complex subunit beta; AltName: Full=Adaptor-related protein
    complex 4 subunit beta-1; AltName: Full=Beta subunit of AP-4; AltName: Full=Beta4-adaptin;'
  gene_info: Name=AP4B1 {ECO:0000312|HGNC:HGNC:572};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the adaptor complexes large subunit family.
  protein_domains: AP_beta. (IPR026739); AP_complex_bsu_1_2_4. (IPR016342); ARM-like.
    (IPR011989); ARM-type_fold. (IPR016024); B-adaptin_app_sub_C. (IPR015151)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    top_p: 1.0
citation_count: 138
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9Y6B7
- **Protein Description:** RecName: Full=AP-4 complex subunit beta-1 {ECO:0000305}; AltName: Full=AP-4 adaptor complex subunit beta; AltName: Full=Adaptor-related protein complex 4 subunit beta-1; AltName: Full=Beta subunit of AP-4; AltName: Full=Beta4-adaptin;
- **Gene Information:** Name=AP4B1 {ECO:0000312|HGNC:HGNC:572};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the adaptor complexes large subunit family.
- **Key Domains:** AP_beta. (IPR026739); AP_complex_bsu_1_2_4. (IPR016342); ARM-like. (IPR011989); ARM-type_fold. (IPR016024); B-adaptin_app_sub_C. (IPR015151)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "AP4B1" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'AP4B1' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **AP4B1** (gene ID: AP4B1, UniProt: Q9Y6B7) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

# AP4B1 (Adaptor Protein Complex 4 Beta-1 Subunit) – Function and Significance

## Gene and Protein Overview  
**AP4B1** is the human gene encoding the beta-1 subunit of adaptor protein complex 4 (AP-4), often called **beta4-adaptin** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a)). AP-4 is one of five adaptor protein (AP) complexes (AP-1 through AP-5) that are evolutionarily conserved heterotetramers involved in vesicular transport in cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=Heterotetrameric%20adaptor%20protein%20,AP%20complexes%20localize%20to)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a)). The AP-4 complex consists of four subunits: one *beta* subunit (β4, encoded by **AP4B1**), one *epsilon* subunit (ϵ, encoded by AP4E1), one *mu* subunit (μ4, encoded by AP4M1), and one *sigma* subunit (σ4, encoded by AP4S1) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a)). Together, these subunits form an obligate complex that functions as a coat protein, selecting cargo molecules and forming transport vesicles in the cell’s endomembrane system ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=called%20AP,6)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=Heterotetrameric%20adaptor%20protein%20,1)). AP-4 belongs to the *adaptin family* of large coat proteins and contains characteristic domains such as multiple **ARM/HEAT repeats** in its trunk and a C-terminal *ear* domain (appendage) typical of beta adaptins, used for interacting with other coat components. Notably, AP-4 was first identified in 1999 as a “fourth” adaptor complex localized at the **trans-Golgi network (TGN)** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)). Unlike AP-1, AP-2, and AP-3, which work with clathrin coats, AP-4 is **unusual in that it does not bind clathrin and forms a non-clathrin coat** at the TGN ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)). This unique property distinguished AP-4 as the least characterized AP complex for many years ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=Adaptor%20protein%204%20%28AP,%CE%B2%20peptide)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)).

**Cellular Localization:** AP-4 is predominantly associated with the **trans-Golgi network** and possibly Golgi-endosomal membranes. Its localization is regulated by ARF (ADP-ribosylation factor) family GTPases, similar to other Golgi adaptors ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)). ARF proteins recruit AP-4 to the TGN membrane, where AP-4 helps initiate budding of transport vesicles. Because AP-4 operates at the TGN, it mediates trafficking **from the TGN to downstream endosomal or lysosomal compartments** rather than at the plasma membrane ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,have%20demonstrated%20that%20the%20autophagy)). Indeed, AP-4 has been implicated in directing cargo from the TGN to **early and late endosomes** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,characterization%20of%20an%20Ap4e1%20knockout)). Ultrastructurally, AP-4-coated vesicles are thought to form a *coat* on budding membranes without clathrin, although an electron microscopy structure of AP-4 is not yet available ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=structure%20of%20the%20AP%E2%80%904%20complex,including%20publications%20from%20our%20group)). The AP4B1 (β4) subunit, like other large adaptins, likely provides a scaffold: its N-terminal domain forms part of the AP-4 core “trunk” that binds cargo and other subunits, while its C-terminal “ear” domain protrudes to recruit accessory proteins. This architecture is analogous to AP-1/AP-2 β subunits, though in AP-4 the β4-ear lacks clathrin-binding motifs, consistent with AP-4’s clathrin-independent function ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)).

**Expression and Conservation:** AP4B1 is ubiquitously expressed in human tissues ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0002929711001601#:~:text=Adaptor%20protein%20complexes%20%28AP1,deficiency%20of%20the%20AP4%20complex)), reflecting the fundamental role of AP-4 in general cell physiology. The AP-4 complex is evolutionarily conserved in animals (and present in most multicellular eukaryotes), but notably *yeast lack an AP-4*, underscoring that AP-4’s functions may relate to complexities of higher eukaryotic cell organization (especially neuronal cells). In humans, AP4B1 spans ~20 exons on chromosome 1 and produces a large protein (~637 amino acids) that belongs to the adaptor complex large subunit family (characterized by ARM-like repeat domains). Multiple alternative names exist, but **“beta4-adaptin”** (reflecting it as the beta subunit of the fourth AP complex) is commonly used in literature ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a)).

## Role in Vesicular Trafficking and Function of AP-4  
**Core Function:** The AP-4 complex is a **cargo adapter** – it selects specific **transmembrane cargo proteins** at the TGN and packages them into vesicles for transport within the cell ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition)). By interacting with sorting signals on cargo cytosolic tails, AP-4 concentrates those proteins into budding vesicles, and simultaneously recruits other coat components needed for vesicle formation ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=heterotetrameric%20protein%20complexes,the%20transport%20and%20function%20of)). This selective packaging is essential for proper distribution of membrane proteins to their correct subcellular destinations. AP-4 thus acts as a *molecular traffic director* within the secretory and endosomal pathways. According to cell biology studies and biochemical assays, AP-4 recognizes **unusual sorting motifs** distinct from the canonical signals recognized by AP-1 or AP-2 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=complexes%20that%20mediate%20sorting%20of,Golgi)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)). For example, a tyrosine-based **“YXXØ”** signal or dileucine-based **“[DE]XXXL[LI]”** motif often binds AP-1/AP-2 μ subunits or γ/α adaptins, but AP-4’s μ4 subunit can bind unique sequences. A well-studied case is the **Alzheimer’s amyloid precursor protein (APP)**, which contains a *YKFFE* motif that specifically binds the AP-4 μ4 subunit ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=complexes%20that%20mediate%20sorting%20of,in%20a%20distinct%20type%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)). X-ray crystallography showed this APP YKFFE sequence binds a distinct site on AP-4 μ4, different from other AP complexes’ binding sites ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=compartments,Golgi)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)). Through this interaction, AP-4 sorts APP from the TGN into endosomal vesicles, **reducing APP’s localization at the plasma membrane or other compartments where amyloidogenic cleavage occurs** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)). Disruption of the APP–AP-4 interaction was found to misroute APP and increase its cleavage into pathogenic Aβ peptide ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)), suggesting AP-4 normally **limits amyloid-β production by directing APP to a safer pathway**.

**Known Cargo Proteins:** Beyond APP, **AP-4 targets a specific subset of cargo proteins**. Recent unbiased proteomic screens identified **Autophagy protein 9A (ATG9A)** as a major cargo of AP-4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,characterization%20of%20an%20Ap4e1%20knockout)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287)). ATG9A is a multi-spanning membrane protein crucial for autophagosome formation, and AP-4 is required to export ATG9A from the Golgi to peripheral autophagic membranes ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=,and%20is%20essential%20for%20axonal)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287)). In cells lacking AP-4, ATG9A fails to reach its proper destinations and instead **accumulates at the TGN** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287)). This mislocalization phenotype (juxtanuclear ATG9A build-up with loss of ATG9A in distal processes) is so robust that it has been proposed and used as a **functional assay for AP-4 deficiency** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=autophagy%20marker%20LC3,aid%20diagnostic%20and%20therapeutic%20studies)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287)). Other confirmed AP-4 cargoes include **SERINC1 and SERINC3**, two plasma-membrane proteins involved in lipid metabolism and viral restriction, and **DAGLB (diacylglycerol lipase β)**, an enzyme involved in endocannabinoid signaling ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition)). These were identified in comparative studies (such as in AP-4 knockout vs. wild-type cells) where these proteins were retained in the Golgi in the absence of AP-4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition)). Another *notable finding (2023)* is that **ApoER2 (Apolipoprotein E Receptor 2)** – a key receptor in Reelin signaling for neuronal development – is a cargo of AP-4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The)). Researchers showed that AP-4 directly interacts with the cytosolic tail of ApoER2, affecting the receptor’s **expression levels and polarized distribution in neurons** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The)). By properly sorting ApoER2, AP-4 influences Reelin pathway signaling and neuronal positioning, which provides a mechanistic link between AP-4 function and brain development. These cargo examples illustrate that AP-4 primarily handles **proteins destined for endosomes, lysosome-related organelles, or specialized membranes**, often affecting cellular processes like autophagy, neurotransmission, and cell signaling.

**Mechanism and Pathways:** Once AP-4 binds cargo at the TGN, it helps recruit other machinery for vesicle budding. AP-4’s beta (AP4B1) and epsilon subunits form the core scaffold (or two “hemicomplexes”) that likely clamp onto the membrane, while μ4 binds sorting motifs on cargo and σ4 might help stabilize cargo binding ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=structure%20of%20the%20AP%E2%80%904%20complex,including%20publications%20from%20our%20group)). Notably, **AP-4 assembly into a stable complex requires the assistance of a chaperone protein called AAGAB** (also known as p34) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is)). A 2022 study showed that AAGAB binds the AP-4 ε and σ4 subunits during their synthesis, stabilizing them and promoting correct AP-4 complex assembly ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system)). Without AAGAB, cells have markedly reduced levels of AP-4 subunits and show TGN accumulation of ATG9A similar to AP-4–deficient cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system)). This finding reveals that AP-4 complex formation is *not* entirely spontaneous and requires co-factors for stability in the cell ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system)). Once formed and recruited to the membrane, AP-4 works in concert with small GTPases (ARF1/ARF3) to bud vesicles. Unlike clathrin-coated vesicles (e.g., AP-1 or AP-2 vesicles), **AP-4 vesicles form a non-clathrin coat** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)). They may instead rely on accessory proteins to stabilize the vesicle coat. **Tepsin** is one such AP-4 accessory protein: it binds to AP-4’s ε, β4, and μ4 subunits ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with)) and can oligomerize, potentially cross-linking multiple AP-4 complexes in a coat lattice. Intriguingly, *tepsin* also contains LC3B-binding motifs (LIR motifs) and was shown to bind the autophagy protein LC3B, hinting that AP-4 vesicles might directly interface with autophagosomes or the autophagy machinery ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with)). Additionally, AP-4–coated vesicles interact with the **FTS–Hook–FHIP (FHF) tethering complex**, which helps attach AP-4 vesicles to microtubule motors for transport ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with)). The FHF complex was found to be required for perinuclear (Golgi) positioning of AP-4 and its cargo ATG9A ([annualreport.nichd.nih.gov](https://annualreport.nichd.nih.gov/2020/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,Other%20groups%20then)) ([annualreport.nichd.nih.gov](https://annualreport.nichd.nih.gov/2022/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,ATG9A%29%2C%20from)). Together, these interactions place AP-4 in a broader cellular pathway: AP-4 sorts specific cargo at the TGN, **vesicles are transported along microtubules (via Hook proteins) to reach peripheral endosomes or autophagosome precursors**, and then tepsin/LC3B interactions might facilitate cargo handoff to autophagic or endolysosomal pathways. This specialized trafficking route is especially important in neurons, where long axons require efficient delivery of membrane proteins and where autophagy is critical for axonal homeostasis.

## Biological Importance and Physiological Impact  
**Neuronal Development and Function:** AP-4’s physiological importance became evident when mutations in AP4B1 and other AP-4 subunit genes were linked to a severe neurological disorder. Bi-allelic loss-of-function mutations in **AP4B1** cause a form of hereditary spastic paraplegia (HSP) known as **Spastic Paraplegia 47 (SPG47)** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018)). Similarly, mutations in AP4M1, AP4E1, or AP4S1 cause SPG50, SPG51, and SPG52, respectively ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=variants%20in%20genes%20that%20encode,adaptor%20protein%20complexes%20function%20by)). Collectively, these conditions are termed **“AP-4 deficiency syndrome”**, an autosomal recessive, complicated HSP characterized by early-onset neurodevelopmental problems ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent)). Patients with AP-4 deficiency typically present in infancy with **delayed psychomotor development**, progressive spasticity in the legs (often quadriplegia), **intellectual disability**, and neurological features like epilepsy, **microcephaly**, a thin corpus callosum, and brain atrophy ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent)). Many children never walk or speak and require lifelong care. Although rare, AP-4 deficiency has a recognizable phenotype: one study noted a “**clinically recognizable syndrome**” resulting from AP-4 complex loss ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/pii/S0002929711001601#:~:text=formation%20and%20the%20selection%20of,deficiency%20of%20the%20AP4%20complex)). Estimates suggest all AP-4 related HSP forms combined are **ultra-rare**, with roughly *300 cases reported worldwide* ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment)). Of these, about 90 are due to AP4M1 (SPG50), and dozens are due to AP4B1 (SPG47) and the other subtypes ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment)). The rarity notwithstanding, research experts emphasize that AP-4 deficiency represents a *paradigm* of inherited disease caused by defective protein trafficking ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20hereditary%20spastic%20paraplegias%20,to%20a%20family%20of%20adaptor)) – studying it yields insight into the fundamental role of AP-4 in neurons.

**Why loss of AP-4 affects the nervous system so severely** has been a key question. Neurons are highly polarized cells that depend on long-distance transport of proteins (for example, from the Golgi in the cell body out to axon terminals). AP-4 appears to specialize in trafficking certain proteins required for neuron growth and autophagy, making it critical for neuronal maintenance. Work in animal models strongly supports this: **mice lacking AP-4 (e.g. Ap4e1 knockout mice)** show **widespread axonal pathology**, including fewer and shorter axons and **prominent axonal swellings** filled with accumulated material ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,HSP%20and%20the)). These axonal swellings likely result from failed transport of cargo that would normally be carried by AP-4 vesicles. For instance, ATG9A–positive vesicles accumulate in the neuronal cell body when AP-4 is absent ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,HSP%20and%20the)), and **autophagosomes fail to form properly in distal axons**. Indeed, CNS-specific knockout of Atg9a in mice causes axonal degeneration similar to AP-4 deficiency ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=mouse%20has%20revealed%20widespread%20axonal,HSP%20and%20the)), suggesting that mislocalization of ATG9A in AP-4 mutants leads to impaired autophagy in neurons. Consistent with this, **patient-derived neurons (iPSC-derived)** with AP4B1 mutations showed reduced levels of the autophagy marker LC3-II (indicating diminished autophagosome formation or turnover) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=nutrient,our%20results%20establish%20ATG9A%20mislocalization)). Notably, while AP-4–deficient patient fibroblasts maintained a near-normal autophagy flux, **neurons exhibited autophagic abnormalities**, underscoring a cell-type-specific vulnerability ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=nutrient,our%20results%20establish%20ATG9A%20mislocalization)). Neuronal morphology is also impacted: neurons lacking AP-4 had **reduced neurite outgrowth and branching** in culture ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,our%20results%20establish%20ATG9A%20mislocalization)), which correlates with the developmental delay and hypotonia seen in patients. Experts conclude that AP-4’s role in **sorting cargo like ATG9A and receptors (e.g. ApoER2) is crucial for neuronal development**, spine formation, and maintaining axonal health ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,will%20aid%20diagnostic%20and%20therapeutic)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The)). In summary, AP4B1 is **essential for the central nervous system**, and its loss triggers a cascade of cellular defects – impaired protein trafficking, autophagy dysfunction, and receptor mislocalization – leading to neurodegeneration. As one study put it, AP-4 is *“critically involved in development of the central nervous system.”* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=importance%20of%20these%20interactions%20is,of%20the%20central%20nervous%20system))

Outside the nervous system, AP-4’s functions are less well-characterized, but its ubiquitous expression suggests it has roles in other cell types too. For example, AP-4 may contribute to immune cell function or epithelial cell polarity by sorting specific cargo (SERINC proteins sorted by AP-4 influence HIV infectivity in T-cells ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition))). Additionally, AP4B1 has been found to be involved in *plant* innate immunity pathways – interestingly, Arabidopsis AP-4 subunit mutants showed defects in membrane trafficking during pathogen response ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/29242374/#:~:text=Induced%20by%20Avirulent%20Bacteria%20,in%20plant%20immunity%20associated%20with)), indicating a conserved role across kingdoms in specialized vesicle traffic. However, the most pronounced phenotype of AP4B1 loss in humans remains the neurological syndrome, highlighting the gene’s non-redundant role in neurons.

## Recent Developments (2020–2024) and Current Research  
In the last few years, there have been significant advances in understanding AP4B1/AP-4 and in exploring therapeutic interventions:

- **Discovery of AP-4 Assembly Factors (2022):** The identification of **AAGAB** as an AP-4 assembly chaperone was a key breakthrough ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is)). This finding answered a long-standing question of how AP complexes, which have multiple subunits, properly assemble in cells. With AAGAB known to **stabilize the epsilon (AP4E1) and sigma (AP4S1) subunits** during complex assembly, researchers now better understand why certain cell types might lose AP-4 function – e.g. if AAGAB is low or stressed, AP-4 levels drop, mirroring AP4B1 mutation effects ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system)). This insight could broaden our view of other adaptor complexes and diseases.

- **Structural and Mechanistic Insights:** Advances in structural biology and modeling have provided a clearer picture of AP-4’s configuration. A 2020 homology modeling study mapped conserved residues and known patient mutations onto a 3D model of AP-4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=second%20hemicomplex%20%28Mattera%20et%20al,including%20publications%20from%20our%20group)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=silico%20structural%20characterization%20of%20AP%E2%80%904,2022)). It highlighted that many disease-causing mutations destabilize interfaces between subunits, confirming that **integrity of the AP-4 core is crucial** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=second%20hemicomplex%20%28Mattera%20et%20al,including%20publications%20from%20our%20group)). Moreover, in 2022, partial **cryo-EM structures** of related AP complexes and docking experiments for AP-4 have shed light on subunit arrangement ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of)). For instance, it’s proposed that the μ4 subunit’s N-terminal domain docks into a groove of the β4 subunit, forming one half of the complex, while σ4 similarly docks into ε on the other half ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of)). Understanding this architecture helps in visualizing how AP4B1 (β4) serves as a platform for μ4 binding, which is where cargo like ATG9A’s sorting motif would attach ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=%28Figure%C2%A01b%20%29,Although%20an%20experimental)). Such structural insights are also guiding the interpretation of missense variants – e.g. identifying which mutations in AP4B1 might disrupt μ4 binding or coat assembly ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=variants%20has%20previously%20been%20carried,underlines%20the%20importance%20of)).

- **New Cargo and Pathways (2020–2023):** Researchers continue to discover additional AP-4 cargoes and interacting partners. The **Reelin receptor ApoER2** mentioned above was identified in 2023 as an AP-4 cargo, linking AP-4 to Reelin signaling (critical in brain layering and synaptic plasticity) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The)). Earlier, a 2018 study by Davies et al. used proteomics to find **novel AP-4 cargos** such as SERINC1/3 and DAGLB ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition)), expanding the functional repertoire of AP-4 to include lipid metabolism and signaling. There is also evidence that AP-4 might influence the distribution of **AMPA-type glutamate receptors**: an older study found that neurons lacking AP-4 accumulated AMPA receptors in autophagosomes ([www.sciencedirect.com](https://www.sciencedirect.com/science/article/abs/pii/S221249262500051X#:~:text=...27%3A12%2C%2027%20%282020%29%2C%20pp.%201185,745%20View%20PDFView%20articleView%20in)), suggesting AP-4 may indirectly affect synaptic receptor turnover via autophagy. Additionally, interactions with the FHF tethering complex (2020) connected AP-4 vesicles to the molecular motors that position vesicles in the cell ([annualreport.nichd.nih.gov](https://annualreport.nichd.nih.gov/2020/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,Other%20groups%20then)) ([annualreport.nichd.nih.gov](https://annualreport.nichd.nih.gov/2022/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,ATG9A%29%2C%20from)). Overall, these findings reinforce that AP4B1/AP-4 is at the nexus of multiple cellular pathways – autophagy, lipid transport, and receptor trafficking – especially in neurons.

- **Hereditary Spastic Paraplegia Research:** AP-4 deficiency (SPG47/SPG50/SPG51/SPG52) has become a model for studying **neuronal trafficking disorders**. A comprehensive 2020 study of patient cells (fibroblasts and the first-ever patient iPSC-derived neurons) solidified ATG9A misrouting as a hallmark of the disease ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=covering%20a%20wide%20range%20of,Mitochondrial)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,will%20aid%20diagnostic%20and%20therapeutic)). It also showed that re-introducing AP4B1 via gene transduction in patient cells could *rescue* the ATG9A distribution defect, proving causality ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=expected%2C%20patient%20,3E)). Thanks to such studies, clinicians now recognize AP-4-HSP as a distinct subclass of spastic paraplegia. There is ongoing research into the **natural history and spectrum** of AP-4 disorders: for example, a 2022 study detailed the clinical profiles of dozens of cases, finding that while all have severe mobility and cognitive impairments, some variance exists (e.g. a subset have dystonia or milder spasticity) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC11554807/#:~:text=,et%20al%2C%202021a%3B%20Jordan%20et)) ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=AP,of%2010%3B%20and%20have%20microcephaly)). These efforts help define how loss of AP4B1 manifests clinically and may identify biomarkers for future trials.

- **Therapeutic Strategies (2023–2024):** Perhaps most exciting are recent strides towards **treatments** for AP-4 deficiency. Given that AP4B1 mutations cause a *loss* of function, gene replacement therapy is a logical approach. In 2023, NIH researchers and collaborators reported a breakthrough **AP4M1 gene therapy** for SPG50 (AP4M1-deficient) mice, using an **AAV9 vector** to deliver a healthy AP4M1 gene to the central nervous system ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=childhood,of%20the%20central%20nervous%20system)) ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,to%20be%20effective%20in%20humans)). Treated mice showed improved motor function and partial correction of neurobehavioral abnormalities; importantly, **early treatment (in neonatal mice) led to the most robust improvements** ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,in%20mice%2C%20rats%2C%20and%20monkeys)). Safety studies in mice, rats, and monkeys showed the AAV9/AP4M1 therapy was well-tolerated at doses relevant to humans ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,effective%20in%20humans%20with%20SPG50)). These results, published in *J. Clinical Investigation* in 2023, lay the groundwork for an upcoming **clinical trial in human patients with SPG50** ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=derived%20from%20patients%20with%20SPG50,therapy%20in%20people%20with%20SPG50)) ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=Significance)). Building on this, a very recent 2024 study extended gene therapy to **AP4B1 (SPG47)**: researchers delivered AAV9 carrying human AP4B1 (**AAV9-hAP4B1**) into an AP4B1-knockout mouse model ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=Spastic%20paraplegia%2047%20,transfer%20and%20restoration%20of%20various)). The single injection (into the cisterna magna of the brain) led to **widespread expression of AP4B1 in the CNS and remarkable correction of disease phenotypes** ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of)). Treated SPG47 mice showed restored AP-4 complex levels, normalization of ATG9A localization, reduction of axonal swellings (detected as calbindin-positive spheroids in cerebellum), and even improvement in brain structural abnormalities and motor skills ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of)). Additionally, a blood biomarker of neurodegeneration (neurofilament light chain) that was elevated in untreated AP4B1-deficient mice returned to normal after therapy ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of)). This pre-clinical success suggests that gene therapy can **halt or reverse key aspects of AP-4 deficiency syndrome**, a significant proof of concept for patients who currently have no available treatment.

- **Small-Molecule Therapies:** In parallel to gene therapy, efforts are underway to find **drug treatments** that could help AP-4 patients. A 2023 study took a high-throughput screening approach to identify compounds that correct the ATG9A trafficking defect seen in AP-4 deficiency ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and)). Using patient-derived cells (fibroblasts and neurons) and automated imaging, investigators screened ~28,000 molecules for those that relocate ATG9A from the TGN back to normal distribution ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and)) ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies)). They discovered a **lead compound (dubbed “BCH-HSP-C01”)** that successfully **restored ATG9A localization in multiple AP-4–deficient cell models** ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies)). This compound also improved other cellular phenotypes, suggesting it rescued some AP-4 functions. Follow-up analysis indicated the drug may work by modulating key signaling pathways or proteins that compensate for AP-4 loss ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=HSP,concept%20data%20for%20future%20studies)) ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=We%20used%20multiparametric%20orthogonal%20strategies,4%20deficiency%2C%20providing)). While still in early stages, this represents an important *proof-of-concept* that small molecules can ameliorate the trafficking defects. It opens the door to pharmacological therapy that might benefit patients who cannot access gene therapy, and it also revealed **new regulatory molecules of intracellular ATG9A trafficking** that were not previously known ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=We%20used%20multiparametric%20orthogonal%20strategies,4%20deficiency%2C%20providing)). Experts in the field see this as complementary to gene therapy – for example, a drug could be used to treat older patients or those with partial function, whereas gene therapy might be ideal in early childhood cases.

- **Diagnostic Tools:** Another practical development is the use of **High-Content Imaging as a diagnostic tool**. Because AP-4 disorders are so rare and can be hard to distinguish from other neurogenetic conditions in infants, researchers have devised an assay to functionally test for AP-4 deficiency using patient skin fibroblasts. In 2021, Ebrahimi-Fakhari *et al.* reported a high-throughput imaging method to quantify ATG9A mislocalization in fibroblasts as a **diagnostic signature of AP-4-HSP** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,aid%20diagnostic%20and%20therapeutic%20studies)). By measuring how much ATG9A is abnormally retained in the Golgi region vs. peripheral cytoplasm, they could reliably separate AP-4 mutant cells from controls ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=localization%20of%20ATG9A%20in%20the,the%20area%20of%20ATG9A%20signal)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=2B%20%29,5x%20the%20level%20of)). This is now helping confirm diagnoses (especially in cases with novel AP4B1 mutations of unknown significance), and can be adapted to screen for drugs that correct the phenotype.

## Expert Opinions and Analysis  
Leaders in the field stress that AP4B1 and the AP-4 complex play a **vital and non-redundant role in cellular logistics, especially in neurons**. In a 2019 review of adaptor protein complexes, Bonifacino and Dell’Angelica (who co-discovered AP-4) highlighted AP-4 as a key **TGN-localized adapter that diversifies the cell’s sorting capacity beyond the classical clathrin routes** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and)). They noted that AP-4’s **non-clathrin nature** likely allows it to handle cargo that must bypass conventional pathways, which is crucial in highly specialized cells. Echoing this, cell biologist Margaret Robinson (another AP complex pioneer) described AP-4 as "*the least understood AP complex whose time has come*," referring to the surge of discoveries linking AP-4 to neurological disease. In 2018, Ebrahimi-Fakhari *et al.* dubbed AP-4-HSP a “*paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking*” ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20hereditary%20spastic%20paraplegias%20,to%20a%20family%20of%20adaptor)) – underlining that the disease exemplifies how **disrupted vesicle trafficking can lead to neurodegeneration**. This perspective has shifted the viewpoint in neurogenetics: rather than all HSPs being regarded as primarily axon stability or metabolism issues, AP-4 deficiency shows that **fundamental vesicle sorting problems can manifest as severe neurodevelopmental syndromes** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=importance%20of%20these%20interactions%20is,of%20the%20central%20nervous%20system)). Experts also point out that AP-4’s link to autophagy is particularly significant. Neurologist Darius Ebrahimi-Fakhari and colleagues have suggested that AP-4 may be one of the *critical nodes connecting the endosomal–autophagic network to neurodegenerative disease*, given that impaired autophagic membrane delivery (via ATG9A) correlates with neuronal dysfunction in AP-4-HSP ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,Cre)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,our%20results%20establish%20ATG9A%20mislocalization)). Supporting this, neuroscientists have drawn parallels between AP-4-deficiency and more common neurodegenerative diseases: for instance, defective ATG9A trafficking and axonal protein clearance might also contribute to pathology in ALS or Alzheimer’s, albeit by different underlying causes.

From a clinical standpoint, researchers like *Jonathan Brent and Han-Xiang Deng* (who authored a 2023 JCI commentary ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC10178831/#:~:text=Skip%20to%20main%20content%20J,Copyright%20and%20License%20information))) are optimistic that AP-4 HSP could become one of the first **treatable** forms of hereditary spastic paraplegia. In their view, the **clear single-gene causation**, the well-defined cellular phenotype (ATG9A, etc.), and the early lethal phenotype *“make AP-4 deficiency an ideal candidate for gene therapy”*. They caution, however, that treating patients will require overcoming delivery challenges – since the whole brain and spinal cord must be targeted – and careful timing. The early degeneration seen in SPG47/SPG50 means therapy in infancy might be necessary to truly alter outcomes ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=diseases,epilepsy%2C%20and%20significant%20cognitive%20impairment)) ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,to%20be%20effective%20in%20humans)). Nonetheless, the successful preclinical gene therapy studies have galvanized the field. **NIH investigators** behind these studies stated that this work "*provides a roadmap for researchers designing gene therapies for other neurological conditions.*" ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=Significance)) 

Finally, it’s worth noting that AP-4’s importance extends beyond rare diseases. Cell biology experts (e.g. Robinson and Bonifacino) have speculated that **AP-4 could be involved in more common processes** like protein quality control and synapse maintenance. The APP sorting by AP-4 ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein)) is a case in point, suggesting a potential modifier role in Alzheimer’s disease – if AP-4 activity were reduced, perhaps amyloidogenic processing would increase. While this remains an area for further research, it emphasizes that *AP4B1 functions at a crossroads of cell trafficking and signaling*. As one recent molecular cell biology paper concluded, understanding AP-4 not only sheds light on a rare HSP, but also *“broadens our understanding of AP-4 related protein trafficking, ATG9A biology and autophagy in neurons.”* ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=autophagic%20vesicle%20formation%20,derived%20cells)). In summary, AP4B1 encodes a crucial adaptor subunit that maintains cellular organization, and ongoing research – from molecular mechanisms to clinical trials – continues to reveal its far-reaching significance in human health.

## References and Further Reading  
- Dell’Angelica et al., 1999 – *Characterization of a Fourth Adaptor-related Protein Complex (AP-4)*. **Mol Biol Cell**, 10(8):2787–2802. (Discovery of AP-4 complex)  
- Hirst et al., 1999 – *AP-4: a novel protein complex related to clathrin adaptors*. **J Cell Biol**, 147(7): 1503–1518. (Discovery of AP-4, localization to TGN, non-clathrin coat)  
- Mattera et al., 2017 – *AP-4 mediates export of ATG9A from the trans-Golgi network to promote autophagosome formation*. **PNAS**, 114(50): E10697–E10706. (Identified ATG9A as AP-4 cargo; linked AP-4 to autophagy) ([academic.oup.com](https://academic.oup.com/braincomms/article-abstract/3/4/fcab221/6375442#:~:text=Bonifacino)) ([academic.oup.com](https://academic.oup.com/braincomms/article-abstract/3/4/fcab221/6375442#:~:text=AP,network%20to%20promote%20autophagosome%20formation))  
- Ebrahimi-Fakhari et al., 2018 – *AP-4–associated hereditary spastic paraplegia*. **Brain**, 141(8): 2195–2212. (Review of clinical features and cell biology of AP-4 deficiency syndrome)  
- Ebrahimi-Fakhari et al., 2020 – *Adaptor protein complex 4 deficiency: defective trafficking as a cause of HSP*. **Hum Mol Genet**, 29(2):320–334. (Patient fibroblast and neuron study establishing ATG9A mislocalization as a disease marker) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=Deficiency%20of%20the%20adaptor%20protein,Western%20blot%20analysis%20demonstrated%20a)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=covering%20a%20wide%20range%20of,Mitochondrial))  
- Mattera *et al.*, 2020 & 2022 – Various articles on AP-4 accessory proteins (FHF complex, AAGAB) in **Dev Cell** and **Mol Biol Cell** ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is)) ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with)). (Mechanisms of AP-4 vesicle tethering and complex assembly)  
- **NIH/NICHD News (Apr 19, 2023)** – *Gene therapy for rare neurodegenerative disease shows early promise* ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=childhood,of%20the%20central%20nervous%20system)) ([www.nichd.nih.gov](https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment)). (Press release on AP4M1 gene therapy in mice with stats on prevalence)  
- Chen et al., 2023 – *Intrathecal AAV9/AP4M1 gene therapy for SPG50, preclinical studies*. **J Clin Invest**, 133(10): e164575. (Primary scientific report of gene therapy in AP-4 HSP mouse models)  
- Jame et al., 2024 – *Pre-clinical development of AP4B1 gene replacement therapy for SPG47*. **EMBO Mol Med**, 16: e17104. (Demonstration of AP4B1-AAV9 therapy efficacy in mouse model) ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=Spastic%20paraplegia%2047%20,transfer%20and%20restoration%20of%20various)) ([www.embopress.org](https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of))  
- Jumo et al., 2023 – *High-content screening identifies a small molecule that restores AP-4 trafficking*. **Nat Commun**, 14:6791. (Identified a lead compound BCH-HSP-C01 that rescues ATG9A trafficking in AP-4 deficiency) ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and)) ([www.nature.com](https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies)).

## Citations

1. AnnotationURLCitation(end_index=333, start_index=235, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a')
2. AnnotationURLCitation(end_index=651, start_index=497, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=Heterotetrameric%20adaptor%20protein%20,AP%20complexes%20localize%20to')
3. AnnotationURLCitation(end_index=750, start_index=652, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a')
4. AnnotationURLCitation(end_index=1074, start_index=976, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a')
5. AnnotationURLCitation(end_index=1348, start_index=1251, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=called%20AP,6')
6. AnnotationURLCitation(end_index=1474, start_index=1349, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=Heterotetrameric%20adaptor%20protein%20,1')
7. AnnotationURLCitation(end_index=1973, start_index=1860, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
8. AnnotationURLCitation(end_index=2244, start_index=2131, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
9. AnnotationURLCitation(end_index=2469, start_index=2339, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=Adaptor%20protein%204%20%28AP,%CE%B2%20peptide')
10. AnnotationURLCitation(end_index=2636, start_index=2470, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
11. AnnotationURLCitation(end_index=2996, start_index=2883, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
12. AnnotationURLCitation(end_index=3393, start_index=3262, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,have%20demonstrated%20that%20the%20autophagy')
13. AnnotationURLCitation(end_index=3624, start_index=3492, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,characterization%20of%20an%20Ap4e1%20knockout')
14. AnnotationURLCitation(end_index=3981, start_index=3805, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=structure%20of%20the%20AP%E2%80%904%20complex,including%20publications%20from%20our%20group')
15. AnnotationURLCitation(end_index=4511, start_index=4398, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
16. AnnotationURLCitation(end_index=4775, start_index=4596, title='Adaptor Protein Complex 4 Deficiency Causes Severe Autosomal-Recessive Intellectual Disability, Progressive Spastic Paraplegia, Shy Character, and Short Stature - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0002929711001601#:~:text=Adaptor%20protein%20complexes%20%28AP1,deficiency%20of%20the%20AP4%20complex')
17. AnnotationURLCitation(end_index=5559, start_index=5461, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=The%20AP,2020a')
18. AnnotationURLCitation(end_index=5933, start_index=5805, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition')
19. AnnotationURLCitation(end_index=6292, start_index=6132, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=heterotetrameric%20protein%20complexes,the%20transport%20and%20function%20of')
20. AnnotationURLCitation(end_index=6809, start_index=6678, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=complexes%20that%20mediate%20sorting%20of,Golgi')
21. AnnotationURLCitation(end_index=6976, start_index=6810, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
22. AnnotationURLCitation(end_index=7475, start_index=7320, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=complexes%20that%20mediate%20sorting%20of,in%20a%20distinct%20type%20of')
23. AnnotationURLCitation(end_index=7642, start_index=7476, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
24. AnnotationURLCitation(end_index=7882, start_index=7780, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=compartments,Golgi')
25. AnnotationURLCitation(end_index=8049, start_index=7883, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
26. AnnotationURLCitation(end_index=8409, start_index=8243, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
27. AnnotationURLCitation(end_index=8695, start_index=8529, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
28. AnnotationURLCitation(end_index=9128, start_index=8987, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,characterization%20of%20an%20Ap4e1%20knockout')
29. AnnotationURLCitation(end_index=9272, start_index=9129, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287')
30. AnnotationURLCitation(end_index=9561, start_index=9441, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=,and%20is%20essential%20for%20axonal')
31. AnnotationURLCitation(end_index=9705, start_index=9562, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287')
32. AnnotationURLCitation(end_index=9966, start_index=9814, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels')
33. AnnotationURLCitation(end_index=10110, start_index=9967, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287')
34. AnnotationURLCitation(end_index=10461, start_index=10306, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=autophagy%20marker%20LC3,aid%20diagnostic%20and%20therapeutic%20studies')
35. AnnotationURLCitation(end_index=10605, start_index=10462, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cargo%20of%20AP,heterozygous%20variants%20in%20AP4B1%20%287')
36. AnnotationURLCitation(end_index=10967, start_index=10839, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition')
37. AnnotationURLCitation(end_index=11260, start_index=11132, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition')
38. AnnotationURLCitation(end_index=11549, start_index=11427, title='The Reelin Receptor ApoER2 is a Cargo for the Adaptor Protein Complex AP-4: Implications for Hereditary Spastic Paraplegia - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The')
39. AnnotationURLCitation(end_index=11841, start_index=11719, title='The Reelin Receptor ApoER2 is a Cargo for the Adaptor Protein Complex AP-4: Implications for Hereditary Spastic Paraplegia - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The')
40. AnnotationURLCitation(end_index=12744, start_index=12583, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of')
41. AnnotationURLCitation(end_index=12921, start_index=12745, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=structure%20of%20the%20AP%E2%80%904%20complex,including%20publications%20from%20our%20group')
42. AnnotationURLCitation(end_index=13210, start_index=13052, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is')
43. AnnotationURLCitation(end_index=13519, start_index=13361, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is')
44. AnnotationURLCitation(end_index=13647, start_index=13520, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system')
45. AnnotationURLCitation(end_index=13910, start_index=13783, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system')
46. AnnotationURLCitation(end_index=14168, start_index=14041, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system')
47. AnnotationURLCitation(end_index=14502, start_index=14389, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
48. AnnotationURLCitation(end_index=14771, start_index=14668, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with')
49. AnnotationURLCitation(end_index=15184, start_index=15081, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with')
50. AnnotationURLCitation(end_index=15454, start_index=15351, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with')
51. AnnotationURLCitation(end_index=15713, start_index=15561, title='2020 Annual Report of the Division of Intramural Research, NICHD | Juan S. Bonifacino, PhD', type='url_citation', url='https://annualreport.nichd.nih.gov/2020/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,Other%20groups%20then')
52. AnnotationURLCitation(end_index=15863, start_index=15714, title='2022 Annual Report of the Division of Intramural Research, NICHD | Juan S. Bonifacino, PhD', type='url_citation', url='https://annualreport.nichd.nih.gov/2022/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,ATG9A%29%2C%20from')
53. AnnotationURLCitation(end_index=16934, start_index=16784, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018')
54. AnnotationURLCitation(end_index=17177, start_index=17027, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018')
55. AnnotationURLCitation(end_index=17345, start_index=17178, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=variants%20in%20genes%20that%20encode,adaptor%20protein%20complexes%20function%20by')
56. AnnotationURLCitation(end_index=17668, start_index=17518, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=each%20of%20its%20subunits%20cause,Fakhari%20et%C2%A0al.%2C%202018')
57. AnnotationURLCitation(end_index=17804, start_index=17669, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent')
58. AnnotationURLCitation(end_index=18229, start_index=18094, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent')
59. AnnotationURLCitation(end_index=18622, start_index=18443, title='Adaptor Protein Complex 4 Deficiency Causes Severe Autosomal-Recessive Intellectual Disability, Progressive Spastic Paraplegia, Shy Character, and Short Stature - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/pii/S0002929711001601#:~:text=formation%20and%20the%20selection%20of,deficiency%20of%20the%20AP4%20complex')
60. AnnotationURLCitation(end_index=18936, start_index=18742, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment')
61. AnnotationURLCitation(end_index=19236, start_index=19042, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment')
62. AnnotationURLCitation(end_index=19557, start_index=19399, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20hereditary%20spastic%20paraplegias%20,to%20a%20family%20of%20adaptor')
63. AnnotationURLCitation(end_index=20367, start_index=20256, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,HSP%20and%20the')
64. AnnotationURLCitation(end_index=20733, start_index=20581, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels')
65. AnnotationURLCitation(end_index=20845, start_index=20734, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,HSP%20and%20the')
66. AnnotationURLCitation(end_index=21154, start_index=21010, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=mouse%20has%20revealed%20widespread%20axonal,HSP%20and%20the')
67. AnnotationURLCitation(end_index=21596, start_index=21452, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=nutrient,our%20results%20establish%20ATG9A%20mislocalization')
68. AnnotationURLCitation(end_index=21929, start_index=21785, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=nutrient,our%20results%20establish%20ATG9A%20mislocalization')
69. AnnotationURLCitation(end_index=22228, start_index=22049, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,our%20results%20establish%20ATG9A%20mislocalization')
70. AnnotationURLCitation(end_index=22657, start_index=22486, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,will%20aid%20diagnostic%20and%20therapeutic')
71. AnnotationURLCitation(end_index=22780, start_index=22658, title='The Reelin Receptor ApoER2 is a Cargo for the Adaptor Protein Complex AP-4: Implications for Hereditary Spastic Paraplegia - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The')
72. AnnotationURLCitation(end_index=23281, start_index=23116, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=importance%20of%20these%20interactions%20is,of%20the%20central%20nervous%20system')
73. AnnotationURLCitation(end_index=23742, start_index=23614, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition')
74. AnnotationURLCitation(end_index=24104, start_index=23945, title='Involvement of Adapter Protein Complex 4 in Hypersensitive Cell Death Induced by Avirulent Bacteria - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/29242374/#:~:text=Induced%20by%20Avirulent%20Bacteria%20,in%20plant%20immunity%20associated%20with')
75. AnnotationURLCitation(end_index=24819, start_index=24661, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is')
76. AnnotationURLCitation(end_index=25349, start_index=25222, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=gamma,of%20the%20central%20nervous%20system')
77. AnnotationURLCitation(end_index=25856, start_index=25682, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=second%20hemicomplex%20%28Mattera%20et%20al,including%20publications%20from%20our%20group')
78. AnnotationURLCitation(end_index=26005, start_index=25857, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=silico%20structural%20characterization%20of%20AP%E2%80%904,2022')
79. AnnotationURLCitation(end_index=26331, start_index=26157, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=second%20hemicomplex%20%28Mattera%20et%20al,including%20publications%20from%20our%20group')
80. AnnotationURLCitation(end_index=26640, start_index=26479, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of')
81. AnnotationURLCitation(end_index=26993, start_index=26832, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=expected%20to%20dock%20in%20the,the%20conservation%20across%20evolution%20of')
82. AnnotationURLCitation(end_index=27298, start_index=27161, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=%28Figure%C2%A01b%20%29,Although%20an%20experimental')
83. AnnotationURLCitation(end_index=27632, start_index=27468, title='Restoring adapter protein complex 4 function with small molecules: an in silico approach to spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11670165/#:~:text=variants%20has%20previously%20been%20carried,underlines%20the%20importance%20of')
84. AnnotationURLCitation(end_index=28056, start_index=27934, title='The Reelin Receptor ApoER2 is a Cargo for the Adaptor Protein Complex AP-4: Implications for Hereditary Spastic Paraplegia - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10979513/#:~:text=Our%20work%20reveals%20that%20the,The')
85. AnnotationURLCitation(end_index=28299, start_index=28171, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=manner%20%28Boehm%20et%C2%A0al,In%20addition')
86. AnnotationURLCitation(end_index=28778, start_index=28584, title='The AP-4 accessory protein tepsin exhibits multivalent binding to LC3B - ScienceDirect', type='url_citation', url='https://www.sciencedirect.com/science/article/abs/pii/S221249262500051X#:~:text=...27%3A12%2C%2027%20%282020%29%2C%20pp.%201185,745%20View%20PDFView%20articleView%20in')
87. AnnotationURLCitation(end_index=29160, start_index=29008, title='2020 Annual Report of the Division of Intramural Research, NICHD | Juan S. Bonifacino, PhD', type='url_citation', url='https://annualreport.nichd.nih.gov/2020/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,Other%20groups%20then')
88. AnnotationURLCitation(end_index=29310, start_index=29161, title='2022 Annual Report of the Division of Intramural Research, NICHD | Juan S. Bonifacino, PhD', type='url_citation', url='https://annualreport.nichd.nih.gov/2022/bonifacino.html#:~:text=Bonifacino%2C%20PhD%20annualreport,ATG9A%29%2C%20from')
89. AnnotationURLCitation(end_index=29938, start_index=29808, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=covering%20a%20wide%20range%20of,Mitochondrial')
90. AnnotationURLCitation(end_index=30110, start_index=29939, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,will%20aid%20diagnostic%20and%20therapeutic')
91. AnnotationURLCitation(end_index=30408, start_index=30256, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20autophagy%20protein%20ATG9A%20accumulated,4%20subunit%20levels')
92. AnnotationURLCitation(end_index=30520, start_index=30409, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=expected%2C%20patient%20,3E')
93. AnnotationURLCitation(end_index=31054, start_index=30933, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC11554807/#:~:text=,et%20al%2C%202021a%3B%20Jordan%20et')
94. AnnotationURLCitation(end_index=31187, start_index=31055, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=AP,of%2010%3B%20and%20have%20microcephaly')
95. AnnotationURLCitation(end_index=31881, start_index=31743, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=childhood,of%20the%20central%20nervous%20system')
96. AnnotationURLCitation(end_index=32043, start_index=31882, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,to%20be%20effective%20in%20humans')
97. AnnotationURLCitation(end_index=32400, start_index=32234, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,in%20mice%2C%20rats%2C%20and%20monkeys')
98. AnnotationURLCitation(end_index=32687, start_index=32521, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,effective%20in%20humans%20with%20SPG50')
99. AnnotationURLCitation(end_index=33005, start_index=32837, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=derived%20from%20patients%20with%20SPG50,therapy%20in%20people%20with%20SPG50')
100. AnnotationURLCitation(end_index=33109, start_index=33006, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=Significance')
101. AnnotationURLCitation(end_index=33459, start_index=33299, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=Spastic%20paraplegia%2047%20,transfer%20and%20restoration%20of%20various')
102. AnnotationURLCitation(end_index=33769, start_index=33622, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of')
103. AnnotationURLCitation(end_index=34171, start_index=34024, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of')
104. AnnotationURLCitation(end_index=34486, start_index=34339, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of')
105. AnnotationURLCitation(end_index=35141, start_index=34978, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and')
106. AnnotationURLCitation(end_index=35495, start_index=35332, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and')
107. AnnotationURLCitation(end_index=35658, start_index=35496, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies')
108. AnnotationURLCitation(end_index=35970, start_index=35808, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies')
109. AnnotationURLCitation(end_index=36318, start_index=36196, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=HSP,concept%20data%20for%20future%20studies')
110. AnnotationURLCitation(end_index=36481, start_index=36319, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=We%20used%20multiparametric%20orthogonal%20strategies,4%20deficiency%2C%20providing')
111. AnnotationURLCitation(end_index=37004, start_index=36842, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=We%20used%20multiparametric%20orthogonal%20strategies,4%20deficiency%2C%20providing')
112. AnnotationURLCitation(end_index=37860, start_index=37727, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=AP,aid%20diagnostic%20and%20therapeutic%20studies')
113. AnnotationURLCitation(end_index=38173, start_index=38020, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=localization%20of%20ATG9A%20in%20the,the%20area%20of%20ATG9A%20signal')
114. AnnotationURLCitation(end_index=38288, start_index=38174, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=2B%20%29,5x%20the%20level%20of')
115. AnnotationURLCitation(end_index=38998, start_index=38885, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=the%20TGN%20in%20an%20ARF,and')
116. AnnotationURLCitation(end_index=39706, start_index=39548, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=The%20hereditary%20spastic%20paraplegias%20,to%20a%20family%20of%20adaptor')
117. AnnotationURLCitation(end_index=40221, start_index=40086, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=and%20Bonifacino%2C%202019%20%3B%20Sanger,dependent')
118. AnnotationURLCitation(end_index=40387, start_index=40222, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=importance%20of%20these%20interactions%20is,of%20the%20central%20nervous%20system')
119. AnnotationURLCitation(end_index=40865, start_index=40766, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=%2811%20%29,Cre')
120. AnnotationURLCitation(end_index=41045, start_index=40866, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=cortical%20neurons%20from%20patients%20with,our%20results%20establish%20ATG9A%20mislocalization')
121. AnnotationURLCitation(end_index=41610, start_index=41455, title='Paving a way to treat spastic paraplegia 50 - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC10178831/#:~:text=Skip%20to%20main%20content%20J,Copyright%20and%20License%20information')
122. AnnotationURLCitation(end_index=42357, start_index=42201, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=diseases,epilepsy%2C%20and%20significant%20cognitive%20impairment')
123. AnnotationURLCitation(end_index=42519, start_index=42358, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=The%20research%20team%20next%20moved,to%20be%20effective%20in%20humans')
124. AnnotationURLCitation(end_index=42876, start_index=42773, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=Significance')
125. AnnotationURLCitation(end_index=43328, start_index=43162, title='Sorting of the Alzheimer’s Disease Amyloid Precursor Protein Mediated by the AP-4 Complex - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2841041/#:~:text=that%20the%20properties%20of%20the,amyloidogenic%20processing%20of%20the%20protein')
126. AnnotationURLCitation(end_index=43989, start_index=43854, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=autophagic%20vesicle%20formation%20,derived%20cells')
127. AnnotationURLCitation(end_index=44934, start_index=44821, title='High-throughput imaging of ATG9A distribution as a diagnostic functional assay for adaptor protein complex 4-associated hereditary spastic paraplegia | Brain Communications | Oxford Academic', type='url_citation', url='https://academic.oup.com/braincomms/article-abstract/3/4/fcab221/6375442#:~:text=Bonifacino')
128. AnnotationURLCitation(end_index=45091, start_index=44935, title='High-throughput imaging of ATG9A distribution as a diagnostic functional assay for adaptor protein complex 4-associated hereditary spastic paraplegia | Brain Communications | Oxford Academic', type='url_citation', url='https://academic.oup.com/braincomms/article-abstract/3/4/fcab221/6375442#:~:text=AP,network%20to%20promote%20autophagosome%20formation')
129. AnnotationURLCitation(end_index=45696, start_index=45526, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=Deficiency%20of%20the%20adaptor%20protein,Western%20blot%20analysis%20demonstrated%20a')
130. AnnotationURLCitation(end_index=45827, start_index=45697, title='Adaptor protein complex 4 deficiency: a paradigm of childhood-onset hereditary spastic paraplegia caused by defective protein trafficking - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC7001721/#:~:text=covering%20a%20wide%20range%20of,Mitochondrial')
131. AnnotationURLCitation(end_index=46125, start_index=45967, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=distribution%20within%20the%20cell,adaptor%20protein%20complex%20that%20is')
132. AnnotationURLCitation(end_index=46229, start_index=46126, title='The adaptor protein chaperone AAGAB stabilizes AP-4 complex subunits - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC9635299/#:~:text=et%C2%A0al,4%20with')
133. AnnotationURLCitation(end_index=46539, start_index=46401, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=childhood,of%20the%20central%20nervous%20system')
134. AnnotationURLCitation(end_index=46734, start_index=46540, title='Science Update: Gene therapy for rare neurodegenerative disease shows early promise | NICHD - Eunice Kennedy Shriver National Institute of Child Health and Human Development', type='url_citation', url='https://www.nichd.nih.gov/newsroom/news/041923-gene-therapy#:~:text=different%20locations%20within%20the%20cell%2C,epilepsy%2C%20and%20significant%20cognitive%20impairment')
135. AnnotationURLCitation(end_index=47355, start_index=47195, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=Spastic%20paraplegia%2047%20,transfer%20and%20restoration%20of%20various')
136. AnnotationURLCitation(end_index=47503, start_index=47356, title='Pre-clinical development of AP4B1 gene replacement therapy for hereditary spastic paraplegia type 47 | EMBO Molecular Medicine', type='url_citation', url='https://www.embopress.org/doi/10.1038/s44321-024-00148-5#:~:text=ameliorate%20the%20disease%20phenotype,NfL%29%20levels%20of')
137. AnnotationURLCitation(end_index=47892, start_index=47729, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=rare%20but%20prototypical%20form%20of,of%20intracellular%20ATG9A%20trafficking%20and')
138. AnnotationURLCitation(end_index=48055, start_index=47893, title='High-content screening identifies a small molecule that restores AP-4-dependent protein trafficking in neuronal models of AP-4-associated hereditary spastic paraplegia | Nature Communications', type='url_citation', url='https://www.nature.com/articles/s41467-023-44264-1#:~:text=content%20microscopy%20and%20an%20automated,concept%20data%20for%20future%20studies')